The differentiation potential of patient-derived cell lines may also be influenced by their genetic background (MYCN amplification and ALK mutation status), the stage of developmental maturation at which progenitors are stalled, intra-tumoral heterogeneity and whether the tumours have undergone prior treatment. This evidence concerns the gene MYCN and neoplasm.